After months of negotiations, the EU and US reached an agreement to levy a 15% tariff on EU imports, which includes including tariffs on specific sectors, like the drug imports.
On this episode, the healthcare reporting team dives into the latest round of tariffs and other regulatory policies that are set to directly affect the pharma sector.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData Insights editor Manasi Vaidya sat down to discuss the news with Robert Barrie, a reporter for Pharmaceutical Technology, who has written about several of these developments in the last few weeks.
The second half of the episode also contains snippets of an interview with Dr. Mariana Socal, a health economist from the Johns Hopkins Bloomberg Public School of Health, about the short and long term consequences of these policies on the development and pricing for these drugs.
Navigate the shifting tariff landscape with real-time data and market-leading analysis.
Request a free demo for GlobalData’s Strategic Intelligence here.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
